Scientific Presentations and Publications

Publications

Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S, for the Marzeptacog alfa (activated) Study Group Investigators. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. J Thromb Haemost 2018; 16: 1984–93.


Scientific Presentations

Molecular Evolution and Design of Pegylated CB 2782 as a Complement Factor C3-Inactivating Protease for Dry AMD
Catalyst Biosciences at the ASBMB Conference – September 15, 2019

A Comprehensive In Silico and In Vitro Immunogenicity Risk Assessment of Dalcinonacog Alfa Shows No Increased Risk Compared with Wild-Type FIX
Catalyst Biosciences at the HDD 2019 meeting – August 21, 2019

A Tale of Two Subcutaneous Engineered Coagulation Factors
Catalyst Biosciences at the HDD 2019 meeting – August 21, 2019

ISTH 2019 - Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia  A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics
Catalyst Biosciences at the ISTH 2019 meeting – July 6-10, 2019

Phase 2/3 trial of subcutaneous engineered FVIIa marzeptacog alfa (activated) in hemophilia A or B with inhibitors: Pharmacokinetics, pharmacodynamics, efficacy and safety
Catalyst Biosciences at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders – February 6-8, 2019

Catalyst Biosciences Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
Catalyst Biosciences Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia ProgramsDecember 18, 2018

Phase 1 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant ISU304/CB 2679d: Pharmacokinetics, Activity and Safety
Catalyst Biosciences, Inc. at the World Federation of Hemophilia 2018 Congress – May 22, 2018

Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant CB 2679d/ISU304: Pharmacokinetics, Activity and Safety
Catalyst Biosciences, Inc. at 11th Annual Congress of the European Association for Haemophilia and Allied Disorders – February 09, 2018

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB 2679d/ISU304: Pharmacokinetics and Activity
Catalyst Biosciences, Inc. at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition – December 09, 2017

Pharmacokinetic & Activity Levels Achieved with Daily Subcutaneously Administered CB 2679d/ISU304 in Hemophilia B Dogs
Catalyst Biosciences, Inc. at the 2017 International Society on Thrombosis and Haemostasis (ISTH) MeetingJuly 10, 2017

Presentation Anti-Complement (C3) for Dry AMD
Anti-Complement (C3) for Dry AMD at OIS Summit – August 08, 2016


Poster Presentations

ISTH 2019 - Quality of Life of Hemophilia Patients with Inhibitors – Opportunities for Improvement
Catalyst Biosciences at the ISTH 2019 meeting – July 6-10, 2019

ISTH 2019 - Phase 2 Trial of Subcutaneous Engineered FIX Dalcinonacog alfa: Pharmacokinetics and Safety
Catalyst Biosciences at the ISTH 2019 meeting – July 6-10, 2019

ISTH 2019 - A Comprehensive In Silico And In Vitro Immunogenicity Risk Assessment of Dalcinonacog Alfa Shows No Increased Risk Compared With Wild-type FIX
Catalyst Biosciences at the ISTH 2019 meeting – July 6-10, 2019

CB 2782-PEG: a Complement Factor C3-Inactivating Protease and Potential LongActing Treatment for Dry AMD 
Catalyst Biosciences at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)April 28, 2019

AAV Based Hemophilia B Gene Therapy in Mice Using FIX-CB2679d-GT
Catalyst Biosciences at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders – February 6-8, 2019

Quality of Life for Haemophilia Patients with Inhibitors
Catalyst Biosciences at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders – February 6-8, 2019

Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (Activated) An Engineered FVIIa In Hemophilia With Inhibitors -Pharmacokinetics, Pharmacodynamics, Safety and Efficacy
Catalyst Biosciences at the 60th American Society of Hematology Annual Meeting & Exposition, San Diego Convention Center, San Diego, CA – December 01, 2018

Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant Cb2679d/ISU304: Pharmacokinetics and Safety
Catalyst Biosciences at the 64th Annual Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis – July 18, 2018

Phase 2/3 Trial of Subcutaneously Administered Novel FVIIa Variant Marzeptacog Alfa (Activated) In Hemophilia A or B with Inhibitors: Pharmacokinetics, Pharmacodynamics, Safety and Efficacy
Catalyst Biosciences at the 64th Annual Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis – July 18, 2018

Discovery and Planned Optimization of a Complement Factor C3-Inactivating Alterase, CB-2782
Catalyst Biosciences, Inc. at 2018 Association for Research in Vision and Ophthalmology Annual Meeting – April 29, 2018

Pharmacokinetics and Pharmacodynamics of daily Subcutaneously Administered Marzeptacog Alfa (Activated) in Hemophilia dogs
CBIO EAHAD2017 FVIIa SC PK/PD Dogs – February 01, 2017

Pharmacokinetics and Pharmacodynamics of daily Subcutaneously Administered CB2679D/ISU304 in Hemophilia B dogs
CBIO EAHAD2017 FIX SC PK/PD Dogs – February 01, 2017

Pharmacokinetics of Subcutaneously Administered CB 2679D/ISU304 in minipig compared with BeneFIX
CBIO EAHAD2017 FIX SC PK/PD Minipigs – February 01, 2017

Pharmacokinetics of Subcutaneously Administered CB2679D/ISU304 in wild-type and Hemophilia B mice
Catalyst Biosciences, Inc.: Coagulation Factor IX at ASH Annual Meeting – December 03, 2016